Exploratory Investigation of Advanced PET/MRI Metrics for Bladder Cancer Characterization
| Status: | Recruiting |
|---|---|
| Conditions: | Cancer, Cancer, Bladder Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 6/17/2016 |
| Start Date: | May 2014 |
| End Date: | May 2018 |
| Contact: | Andrew Rosenkrantz, MD |
| Email: | andrew.rosenkrantz@nyumc.org |
| Phone: | 212-263-8732 |
The overarching goal of this project is to explore whether associations exist between
metrics obtained from PET/MRI incorporating advanced MRI sequences and features of bladder
cancer, including grade, stage, and treatment response.
metrics obtained from PET/MRI incorporating advanced MRI sequences and features of bladder
cancer, including grade, stage, and treatment response.
The investigators will assess an advanced non-Gaussian diffusion-weighted imaging (DWI)
model termed diffusion kurtosis imaging, multi-echo T2 mapping, dynamic contrast-enhanced
(DCE) MRI using a motion-robust high-temporal and high-resolution radial acquisition scheme
employing compressed sensing, and simultaneously acquired 18-fluoro (18F)-
fluorodeoxygluclose (FDG) data. Preliminary data demonstrates the investigators ability to
execute and evaluate all of these techniques at the investigators center. The investigators
hypothesize that these techniques will be sensitive to functional and metabolic differences
between subsets of bladder cancer cases and will improve upon the performance of current
imaging protocols in bladder cancer characterization. Moreover, the investigators believe
that these techniques will provide complementary information, such that they may be combined
in a synergistic fashion for bladder cancer evaluation.
model termed diffusion kurtosis imaging, multi-echo T2 mapping, dynamic contrast-enhanced
(DCE) MRI using a motion-robust high-temporal and high-resolution radial acquisition scheme
employing compressed sensing, and simultaneously acquired 18-fluoro (18F)-
fluorodeoxygluclose (FDG) data. Preliminary data demonstrates the investigators ability to
execute and evaluate all of these techniques at the investigators center. The investigators
hypothesize that these techniques will be sensitive to functional and metabolic differences
between subsets of bladder cancer cases and will improve upon the performance of current
imaging protocols in bladder cancer characterization. Moreover, the investigators believe
that these techniques will provide complementary information, such that they may be combined
in a synergistic fashion for bladder cancer evaluation.
Inclusion Criteria:
- Histologic or imaging evidence of urothelial carcinoma of the bladder
- Age ≥ 18 years of age
- If female of childbearing potential, pregnancy test is negative. (In these instances,
the patient will need to provide documentation of negative pregnancy test results.)
Exclusion Criteria:
- Inability to tolerate MRI including conditions such as claustrophobia or inability to
lay flat for > 45 minutes.
- Presence of pacemaker/implantable cardiac device (ICD) or perfusion pumps
- Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial
heart, valves with steel parts, metal fragments, shrapnel, bullets, tattoos near the
eye, or steel implants.
- Substance abuse, medical, psychological, or social conditions that may interfere with
the patient's participation in the study
We found this trial at
1
site
New York, New York 10016
Principal Investigator: Andrew Rosenkrantz, MD
Phone: 212-263-2710
Click here to add this to my saved trials
